Alto Neuroscience is a clinical-stage biopharmaceutical company leveraging a Precision Psychiatry Platform to develop personalized psychiatric treatment options. The company measures brain biomarkers through EEG activity, neurocognitive assessments, and wearable data to identify patients more likely to respond to Alto product candidates. Founded in 2019 by Dr. Amit Etkin after over a decade of clinical research at Stanford University, Alto went public on NYSE (ticker: ANRO) in February 2024, raising $147.9 million in gross proceeds.
Alto Neuroscience is publicly traded
IPO'd on February 6, 2024
This company is no longer available on our private secondary market. Shares can be traded publicly under ANRO.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2019
Employees
60–83
Total Funding
$145M
5 rounds
Total raised $145M across 5 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series C
Date
November 21, 2023
Amount
$45M
Valuation
—
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| November 21, 2023 | Series C | $45M | — | InVivium Capital |
| January 30, 2023 | Series B extension | $25M | — | Alpha Wave Ventures |
| October 25, 2022 | Series B | $35M | — | Lightswitch Capital, partners of Alkeon Capital |
Amit Etkin
Founder and CEO
Yes, Alto Neuroscience is publicly traded under the ticker symbol ANRO on the NYSE. The company went public in February 6, 2024.
Alto Neuroscience trades under the ticker symbol ANRO on the NYSE. It began trading in February 6, 2024.
Alto Neuroscience (ANRO on the NYSE) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker ANRO to place an order.
Alto Neuroscience went public in February 6, 2024 via ipo. Alto Neuroscience completed its initial public offering on February 6, 2024, on the New York Stock Exchange under ticker symbol ANRO. The company offered 9,246,000 shares at $16 per share, raising gross proceeds of $147.9 million. The IPO was upsized from the original plan following strong investor demand. Trading began February 2, 2024, opening at $22 per share, well above the IPO price.
Alto Neuroscience raised $145M across 5 disclosed funding rounds prior to its public listing.
Alto Neuroscience was founded by Amit Etkin in 2019.
Alto Neuroscience is headquartered in Mountain View, CA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.